RBM39 and hepatocellular carcinoma: Experiments on cells, mouse models, and patient-derived organoids indicate that molecular glues, like aryl sulfonamide indisulam, which specifically target the ubiquitination and degradation of RBM39, could benefit HCC patients with decreasing levels of tumoral Arg and RBM39 expression [93].